-$0.78 Earnings Per Share Expected for Spero Therapeutics Inc (SPRO) This Quarter

Share on StockTwits

Wall Street brokerages expect Spero Therapeutics Inc (NASDAQ:SPRO) to post earnings of ($0.78) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Spero Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.85) and the highest estimate coming in at ($0.71). Spero Therapeutics reported earnings of ($36.02) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 97.8%. The firm is scheduled to report its next earnings results on Thursday, December 13th.

According to Zacks, analysts expect that Spero Therapeutics will report full year earnings of ($3.20) per share for the current year, with EPS estimates ranging from ($3.85) to ($2.81). For the next financial year, analysts anticipate that the business will report earnings of ($3.73) per share, with EPS estimates ranging from ($4.30) to ($3.30). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Thursday, August 9th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.08. Spero Therapeutics had a negative net margin of 1,479.91% and a negative return on equity of 182.49%. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.62 million.

Several research analysts have commented on SPRO shares. Oppenheimer set a $30.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Monday, July 9th. Cantor Fitzgerald set a $27.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Monday, July 9th. HC Wainwright started coverage on shares of Spero Therapeutics in a report on Friday, May 11th. They set a “buy” rating and a $28.00 price target for the company. Finally, ValuEngine upgraded shares of Spero Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Spero Therapeutics has a consensus rating of “Buy” and an average price target of $25.00.

SPRO traded down $0.03 during trading hours on Friday, hitting $11.27. 68,672 shares of the company’s stock were exchanged, compared to its average volume of 230,178. Spero Therapeutics has a 12-month low of $9.66 and a 12-month high of $19.00. The company has a market cap of $162.37 million and a P/E ratio of -0.63.

In other news, CFO Joel Sendek sold 2,000 shares of the company’s stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $17.50, for a total value of $35,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Plc Glaxosmithkline bought 80,000 shares of the stock in a transaction dated Tuesday, July 17th. The stock was bought at an average price of $12.50 per share, with a total value of $1,000,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 10,676 shares of company stock valued at $187,438 in the last quarter. 26.90% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in Spero Therapeutics by 19,604.3% during the 1st quarter. JPMorgan Chase & Co. now owns 256,353 shares of the company’s stock worth $3,653,000 after purchasing an additional 255,052 shares during the period. BlackRock Inc. acquired a new stake in Spero Therapeutics during the 4th quarter worth $2,830,000. DAFNA Capital Management LLC boosted its stake in Spero Therapeutics by 490.9% during the 1st quarter. DAFNA Capital Management LLC now owns 29,544 shares of the company’s stock worth $421,000 after purchasing an additional 24,544 shares during the period. BVF Inc. IL boosted its stake in Spero Therapeutics by 1.9% during the 1st quarter. BVF Inc. IL now owns 1,048,958 shares of the company’s stock worth $14,948,000 after purchasing an additional 19,773 shares during the period. Finally, Deutsche Bank AG acquired a new stake in Spero Therapeutics during the 4th quarter worth $155,000. Institutional investors and hedge funds own 45.92% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Recommended Story: Using the New Google Finance Tool

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply